Article Text

PDF
P289 Isolated Mediastinal and/or Hilar Lymphadenopathy: what can EBUS-TBNA add?
  1. V Connor,
  2. V Tippet,
  3. T Kennedy,
  4. B Challoner
  1. Aintree University Hospital, Liverpool, UK

Abstract

Introduction and objectives In recent years, endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) has been increasingly used to investigate patients with isolated mediastinal and/or hilar lymphadenopathy (IMHL). There is currently a lack of high quality research to confirm the diagnostic yield and accuracy for these patients.

The aim of this review was to examine the diagnostic yield of EBUS-TBNA in patients with IMHL, to ensure accurate information is being given to patients considering undergoing the procedure.

Methods A retrospective service review was carried out, including consecutive patients listed for EBUS-TBNA between June 2013–June 2014 in a single UK centre.

Results 135 patients were evaluated who underwent EBUS-TBNA as a first diagnostic test (full results in Table 1). 35 patients with IMHL underwent EBUS-TBNA within the study period; IMHL was defined as the presence of enlarged mediastinal/hilar lymph nodes on computer tomography (CT) without suggestion of intrathoracic/extra-thoracic malignancy. 34 of these had a diagnostic test (97%); pathological cause was found in 9 patients (sarcoid n = 7, malignancy n = 2) with the remaining being diagnosed with reactive lymphadenopathy (n = 25 74%).

Abstract P289 Table 1

Results of 135 patients undergoing EBUS-TBNA as a first line investigation for mediastinal and/or hilar lymphadenopathy

This group of 35 patients was sub-classified into those with IMHL with a radiologically suggested diagnosis e.g. sarcoid (n = 22) and those with no suggested cause of IMHL (n = 13). EBUS-TBNA was diagnostic in 95% and 100% of patients respectively with the most common diagnosis in both groups remaining that of reactive lymphadenopathy.

Conclusions A significant proportion of patients with IMHL were found to have a diagnosis of reactive lymphadenopathy. With a pathological cause only being found in a minority of cases the appropriateness of EBUS-TBNA to investigate these patients could be questioned.

Our results found a significantly higher prevalence of reactive lymphadenopathy than previously published data; Evinson et al. reported this diagnosis 48% of patients and the REMEDY trial reported reactive lymphadenopathy in 5% of patients.

The detection of IMHL and its burden on the health service is likely to increase with increasing use of CT. Due to this a large multi-centred prospective study of patients with IMHL would be advisable to further investigate what the most appropriate strategy to manage these patients should be.

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.